Background Minimizing time to HIV viral suppression is critical in pregnancy. Integrase
strand transfer inhibitors (INSTIs), like raltegravir, are known to rapidly suppress plasma HIV …

Background Although antiretroviral regimens containing integrase inhibitors rapidly
suppress HIV viral load in non-pregnant adults, few published data from randomised …

Antenatal screening program for HIV has been in use in Sweden since 1987 with a 95–98%
acceptance rate. Screening is performed during gestational week 10–12 and antiretroviral …

Objectives: Following an alert on neural tube defects and dolutegravir, we sought to
evaluate if the exposure integrase strand transfer inhibitors (INSTIs) at conception was …

Purpose Recommended regimens for pregnant women with HIV-1 are composed of two
nucleoside reverse transcriptase inhibitors (NRTI) plus either a ritonavir-boosted protease …

Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the
latest class of antiretrovirals (ARVs) that have become available to treat human …

Objectives: Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective
treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we …

Background Women are under-represented in HIV antiretroviral therapy (ART) studies.
Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not …

More than fifteen million women with the human immunodeficiency virus type-1 (HIV-1)
infection are of childbearing age world-wide. Due to improved and affordable access to …

Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human
immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve …